Anthem Biosciences IPO Allotment Status, Allotment Date, and GMP

The Anthem Biosciences IPO allotment status will be available on Thursday, July 17, 2025. Investors can check their allotment status on the NSE, BSE, or the official registrar’s website, Kfin Technologies Limited. The IPO opened on July 14, 2025, and by the end of Day 3, it was subscribed 67.42 times. Follow the simple steps below to check your Anthem Biosciences IPO allotment status.

How to Check Anthem Biosciences IPO Allotment Status on NSE

Below are the steps to check the Anthem Biosciences IPO allotment status on NSE:

Step 1: Visit the NSE website page “Verify IPO Bids” 

Step 2: Select the IPO symbol “ANTHEM” from the dropdown menu.

Step 3: Enter the PAN No. and Application No 

Step 4: Click Submit.

Step 5: Once submitted, check the "Allotment Details" section for the IPO allotment status

How to Check Anthem Biosciences IPO Allotment Status on BSE

Follow these simple steps to check the Anthem Biosciences IPO allotment status on BSE:

Step 1: Visit the BSE “Status of Issue Application” page.

Step 2: Select the issue type as “Equity.”

Step 3: Select "Anthem Biosciences Limited" from the Issue Name section.

Step 4: Enter your IPO Application number or PAN number.

Step 5: Tick the “I’m not a robot” box to verify your identity.

Step 6: Click the “Search” button to view the Anthem Biosciences IPO allotment status.

How to Check Sambhv Steel Tubes IPO Allotment on Kfin Technologies

Below are the steps to check the Sambhv Steel Tubes IPO allotment status on the Kfin Technologies  website:

Step 1: Visit the KFin Technologies “IPO Allotment Status” Page.

Step 2: Select Company “Sambhv Steel Tubes Limited” in the Select IPO dropdown menu.

Step 3: Select PAN/Application No/Demat Account in the selection menu.

Step 4: Enter “PAN No”/“Application No”/“DPID Client ID.”

Step 5: Enter Captcha

Step 6: Click on “Submit” to check the allotment status.

Anthem Biosciences IPO Subscription

By the end of Day 3, the Anthem Biosciences IPO was subscribed 67.42 times overall. Qualified Institutional Buyers (QIBs) led the subscriptions with an overwhelming 192.80x, followed by Non-Institutional Investors (NIIs) at 44.70x, while Retail Individual Investors (RIIs) subscribed at 5.98x.

Anthem Biosciences IPO Allotment Details

• IPO Open Date: Monday, 14th July 2025

• IPO Close Date: Wednesday, 16th July 2025

• Allotment Date: Thursday, 17th July 2025

• Initiation of Refunds: Friday, 18th July 2025

• Credit of Shares to Demat: Friday, 18th July 2025

• Listing Date: Monday, 21st July 2025

The Anthem Biosciences IPO has a total issue size of ?3,395.00 crore, consisting entirely of an Offer For Sale (OFS) of 5,95,61,404 shares. There is no fresh issue component in this IPO. The issue price is fixed at ?570 per share, and the minimum lot size is 26 shares.

Anthem Biosciences IPO GMP

According to InvestorGain, the latest GMP (Grey Market Premium) for Anthem Biosciences is 26.49%, which means the shares are expected to list at Rs. 721, giving investors a profit of Rs. 3926 per lot.

Company Overview of Anthem Biosciences IPO 

Anthem Biosciences Limited is an innovation-driven and technology-focused Contract Research, Development, and Manufacturing Organisation (CRDMO). The company offers fully integrated operations spanning drug discovery, development, and manufacturing. Anthem Biosciences is one of the few Indian companies possessing integrated New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities across discovery, development, and commercial manufacturing.

The company provides end-to-end CRDMO services to innovator-focused emerging biotech and large pharmaceutical companies globally. Its CRDMO platform includes five main modalities, such as RNA interference (RNAi), antibody-drug conjugates (ADC), peptides, lipids, and oligonucleotides. It also has four manufacturing capabilities, such as custom synthesis, flow chemistry, fermentation, and biotransformation. Beyond CRDMO services, Anthem Biosciences also manufactures and sells complex, specialised fermentation-based Active Pharmaceutical Ingredients (APIs), including probiotics, enzymes, peptides, and more.

They earn 70.78% from developmental and commercial manufacturing, 10.87% from research and development, and 18.35% from specialty ingredients. As of March 31, 2025, Anthem Biosciences operates two manufacturing facilities in India, Unit I in Bommasandra and Unit II in Harohalli, with Unit III in Harohalli under construction. The total custom synthesis capacity is 270 kL, and the fermentation capacity is 142 kL, and is expected to increase to 425 kL and 182 kL by H1FY26, respectively. The company has a strong focus on sustainable manufacturing practices, with approximately 90% of its energy sourced from renewable sources as of March 31, 2025. The company is led by an experienced team, including founder and CEO Mr. Ajay Bhardwaj.

Quick Steps to Invest in IPOs with Rupeezy

Step 1: Download Rupeezy Trading App 

Step 2: Register and Complete Verification

Step 3: Open the app and Navigate to the IPO Section 

Step 4: Select “Anthem Biosciences”

Step 5: Click on Apply